Zynaxis other research news

ZNXS published the use of its Zyn-linker technology to create membrane anchored, pH sensitive compounds that are internalized into cells and slowly release active drug. As reported in The Journal of Controlled Release, mice with implanted ovarian tumors given a single dose of the slowest-release Zyn-linked colchicine compound survived twice as long as untreated mice, with no signs of toxicity.

The compounds were created to demonstrate the principle of action. Zyn-linked chemotherapeutic drugs might be able to overcome the cellular pump that causes multi-drug resistance in cancer, the researchers added. Other possible uses of the Zyn-linkers could be with antisense oliogonucleotides or with camptothecin analogs, the report concluded. ...